The CD83 molecule is a novel target gene for the aryl hydrocarbon receptor in human dendritic cells
Year: 2020
Type: dissertation
Abstract: Project 1: The ligand-activated transcription factor aryl hydrocarbon receptor (AHR) is a promising therapeutic target for the regulation of dendritic cell (DC)-mediated antigen-specific tolerance in autoimmune diseases. Bioinformatic analyses identified two AHR binding motifs within the CD83 promoter region of human DCs, thereby making CD83 to a potential AHR target gene. Our group showed that the natural low-affinity AHR ligand quercetin impaired the CD83 upregulation in human LPS-matured monocyte-derived DCs (LPS-DCs), and that quercetin-treated LPS-DCs secreted higher levels of IL-1ß, IL-8, TNF-α but lower levels of IL-12p70. In the present study, we compared the synthetic high-affinity ligand TCDD to quercetin to gain more insights into the effects of AHR activation on human DCs. TCDD impaired the CD83 expression in LPS-DCs and altered their cytokine profile similar to quercetin, but IL-12p70 levels were increased. The CD83 suppression induced by both ligands was reversed by the AHR antagonist SR1. Moreover, CD83 transcription was regulated by the binding of AHR to the CD83 promoter. Notably, quercetin, but not TCDD, led to a reduced T cell stimulatory capacity of LPS-DCs and to a higher frequency of regulatory T cells. Quercetin additionally induced the expression of ILT2, ILT3, ILT4, ILT5 as well as CD39 and CD73 in LPS-DCs, thereby pointing to a tolerogenic phenotype. Finally, quercetin reduced the pathology in the murine experimental autoimmune encephalomyelitis (EAE) model. Overall, the data provide phenotypic and functional evidence that quercetin induces tolerogenic properties in human DCs, thereby identifying a potential immunomodulatory agent. Project 2: The CD83 molecule has been related to cancer due to its expression by several tumor cells and soluble CD83 has been described to be present at elevated levels in haematological malignancies such as Hodgkin lymphoma, thereby representing a potential new biomarker. However, it was not known whether CD83 could also be a biomarker for malignant melanoma. Thus, this project aimed to examine the prognostic/diagnostic relevance of CD83 expression on malignant melanoma cells. Therefore, different available melanoma cell lines and patient-derived melanoma cell lines were investigated for their CD83 expression. However, if at all melanoma cells expressed only very low CD83 levels. Even stimulation with PMA and ionomycin or incubation with dabrafenib and/or trametinib did not trigger CD83 expression by the used cells lines. Altogether, from these data we conclude that CD83 does not represent a biomarker for malignant melanoma.
Author: Michalski, Julia
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: CD83, aryl hydrocarbon receptor, dendritic cells, quercetin, TCDD, SR1, IL-12p70, regulatory T cells, tolerogenic dendritic cells, experimental autoimmune encephalomyelitis, immunomodulation, melanoma, prognostic factors, CD39/CD73, Hodgkin's disease, tumor-associated macrophages, tumor-associated neutrophils
Open Access status: green
OpenAlex ID: W7055058817
